Document is current
Any future updates will be listed below
-
Authors
Goday, Albert https://orcid.org/0000-0001-7356-1595
Pérez, Gilberto https://orcid.org/0000-0002-6831-6226
Fernández, Amanda
Díaz-Carrasco, Xavier https://orcid.org/0009-0005-5235-2088
Leis, Rosaura https://orcid.org/0000-0002-0540-4210
de Hollanda, Ana https://orcid.org/0000-0001-9114-8614
Ramon-Krauel, Marta https://orcid.org/0000-0003-3027-9105
-
Funding
Funding for this research was provided by:
Universitat Pompeu Fabra
- License Information
-
More Information
Article History
Accepted: 18 September 2025
First Online: 21 October 2025
Declarations
:
: AG: speaker fees from Novo Nordisk. RL: advisory board fees from Nutricia-DANONE, Novo Nordisk, Lactalis, Nestlé. Speaker fees from Novo Nordisk, Nestlé, Nutricia-DANONE, Ferrer.ADH: advisory board fees from Lilly, Boehringer; speaker fees from Novo Nordisk, Lilly, Rhythm, Almirall. MRK: advisory board fees from Merck, Novo Nordisk, Palobiofarma, Pfizer, Sandoz and Sanofi; speaker fees from Novo Nordisk, Pfizer, Rhythm, and Sandoz.GP, AF and XDC declare no competing interests.
: Clinical trial number: not applicable.
